查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1136901

全球慢性腎病藥物市場2022-2029

Global Chronic Kidney Disease Drugs Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場動態

主要驅動因素是慢性腎病患病率的增加、對治療患者的藥物的持續需求、易於獲得的藥物、研究和開發的增加、技術進步以及市場上老年人口的增長。預計這將成為引擎的增長。

預計對慢性腎病藥物的需求不斷增長將推動市場增長。

全球慢性腎髒病藥物市場主要受慢性腎髒病相關藥物需求增長的推動。根據美國疾病控制與預防中心 2021 年報告，慢性腎病不斷上升會導致更多人死亡。這是一場未被充分認識的公共衛生危機。它影響了美國大約 3700 萬人，佔成年人口的 15%，即超過七分之一的成年人。肥胖、高血壓和糖尿病是慢性腎病的常見原因。因此，對慢性腎病的治療劑的需求不斷增加。

主要市場進入者不斷提高的技術進步正在推動市場的增長。市場上正在進行許多新的研究和創新。例如，2021年4月，阿斯利康宣布Farxiga（達格列淨）獲得美國食品藥品監督管理局的批准。 Faxiga 是一種鈉-葡萄糖協同轉運蛋白 2 的抑製劑，用於最大限度地降低與估計的腎小球濾過率、心血管死亡、終末期腎病和慢性腎病相關的風險。

慢性腎病藥物的高成本和副作用阻礙了市場增長。

由於開具各種藥物以盡量減少慢性腎髒病的發展，從而導致慢性腎髒病患者出現腎功能不全等並發症，因此存在藥物相關並發症、成本高、監管審批程序嚴格、模稜兩可等風險。症狀延遲慢性腎病的診斷、仿製藥選擇趨勢和藥物專利到期。

本報告介紹了全球慢性腎病藥物市場，有 40 多個市場數據表、45 多個圖表和 200 頁（估計）。

內容

第一章市場研究方法和範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第 4 章市場動態

  • 市場影響因素
    • 驅動程序
      • 對慢性腎病藥物的需求增加
      • 技術進步的增加
    • 約束因素
      • 慢性腎病藥物成本高
      • 與 CKD 藥物相關的風險
    • 商機
    • 影響分析

第五章行業分析

  • 波特五力
  • 未滿足的需求
  • 流行病學
  • 供應鏈分析
  • 監管分析

第 6 章 COVID-19 分析

  • COVID-19 的市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按藥物類別

  • 鈣拮抗劑
  • ACE抑製劑
  • B 受體阻滯劑
  • 利尿劑
  • 紅細胞生成刺激劑 (ESAS)
  • 其他

第 8 章給藥途徑

  • 口語
  • 皮下給藥
  • 靜脈給藥

第 9 章按分銷渠道

  • 醫院藥房
  • 零售藥房
  • 在線藥店
  • 其他

第 10 章按地區劃分

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 11 章競爭格局

  • 主要發展和戰略
  • 公司份額分析
  • 產品基準
  • 值得關注的重點公司列表

第 12 章公司簡介

  • 輝瑞公司
    • 公司簡介
    • 產品組合和描述
    • 主要亮點
    • 財務摘要
  • Sanofi S.A.
  • F. Hoffmann-La Roche Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • AstraZeneca Plc.
  • Kissei Pharmaceutical Co
  • AbbVie Inc.
  • GlaxoSmithKline Plc
  • Amgen Inc.
  • Akebia Therapeutics

第13章 全球慢性腎病藥物市場-DataM

簡介目錄
Product Code: DMMD790

Market Overview

The Chronic Kidney Disease Drugs Market was valued at US$ 10,923.29 million in 2021 and is estimated to reach US$ 19,427.41 million by 2029, growing at a CAGR of 6.58% during the forecast period (2022-2029).

Chronic kidney disease, also known as chronic kidney failure, describes the gradual loss of kidney function. Kidneys filter the wastes and excess fluids from blood, which are then excreted in the urine.

Market Dynamics

The major driving forces are the increasing prevalence of chronic kidney disease, the continuous requirement for drugs to treat the patients along with easy availability, the increase in research and development, technological advancements and the rising geriatric population are expected to drive market growth.

The rising requirement for chronic kidney disease drugs is expected to drive market growth.

The global market for chronic kidney disease drugs is primarily driven by the rising demand for drugs related to chronic kidney disease. According to the Centre for Disease Control and Prevention report 2021, the increase in chronic kidney disease causes more deaths. It is an under-recognized public health crisis. It affects approximately 37 million people in the U.S., equivalent to 15% of the adult population or more than one in seven adults. The high prevalence of obesity, hypertension and diabetes are some of the reasons that are causing chronic kidney disease. Hence, increasing demand for drugs for the treatment of chronic kidney disease.

Increasing technological advancements by the major key players are driving the market's growth. Various novel research studies and innovations are taking place in the market. For instance, in Apr 2021, AstraZeneca announced the approval of Farxiga (dapagliflozin) by the U.S. Food and Drug Administration. Farxiga is an inhibitor of sodium-glucose cotransporter 2 used to minimize the risk associated with estimated glomerular filtration rate, cardiovascular death, end-stage kidney disease, and chronic kidney disease patients.

Chronic kidney disease drugs' high cost and side effects will hamper the market's growth.

The risks associated with chronic kidney disease drugs such as medication-related complications as a variety of medications are prescribed to minimize the chronic kidney disease growth that leads to some complications such as renal functions degradation of the patient, the high cost, the stringent regulatory approval process, delayed diagnosis of chronic kidney disease due to vague symptoms, the inclination to generic medication options, and the patent expiry of drugs.

Segment Analysis

The calcium channel blockers segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The calcium channel blockers segment is the highest market holder in the global chronic kidney disease drugs market. The increased number of chronic kidney diseases leads to the growing demand for treatment drugs and research activities. Calcium channel blockers prevent, treat or improve symptoms in various conditions, such as high blood pressure and coronary artery disease, which can increase the risk of chronic kidney diseases. Presently, dominant calcium channel blockers utilized across the world are phenyl alkyl amines (verapamil), benzothiazepines (diltiazem), and dihydropyridines (nifedipine and amlodipine). A report published in Aug 2022 titled "Renal Function in Hypertensive Patients Receiving Cilnidipine and L-Type Calcium Channel Blockers" reported that around 65-95% of patients with chronic kidney disease are suffering from hypertension. The first line of treatment drugs for hypertension are Calcium channel blockers. These calcium channel blockers act as antihypertensive medicines used widely due to their high tolerability, efficacy in lowering the level of blood pressure, and hypertension-related cardiovascular or renal consequences. For instance, in Aug 2022, AstraZeneca from DELIVER phase III trial released detailed results showing Farxiga reducing cardiovascular death or heart failure.

Geographical Analysis

North America holds the largest market share of the global chronic kidney disease drugs market.

North America dominates the global chronic kidney disease drug market, primarily attributed to the growing prevalence of chronic kidney diseases, kidney failure, and diabetes. The rapid adoption of drugs for CKD is likely to enhance the growth of chronic kidney disease drugs. Furthermore, factors such as the high spending of GDP on healthcare, growing government initiatives, and reimbursement policies in advanced medical treatment options are likely to enhance the growth of the region's chronic kidney disease drugs market.

Moreover, extensive research activities are undertaken by the most prominent players in the area, and the rising demand for technologically advanced treatment will propel the market. Also, key players manufacturing chronic kidney disease treatment drugs are boosting the market. For instance, in Jul 2021, Bayer announced the approval of Kerendia (Finerenone), first non-steroidal, mineralocorticoid receptor antagonist, by the U.S. FDA. Finerenone is used to minimize the risk of decline in estimated glomerular filtration rate, cardiovascular death, end-stage kidney disease and chronic kidney disease patients with type 2 diabetes.

Competitive Landscape

The chronic kidney disease drug market is moderately competitive with local and global companies. Key players contributing to the market's growth are Sanofi S.A., F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., AstraZeneca Plc., Kissei Pharmaceutical Co, AbbVie Inc., GlaxoSmithKline Plc, Amgen Inc., Akebia Therapeutics and more.

The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the growth of the cardiac ablation devices market. For instance, in Aug 2022, CSL Limited announced the completion of the acquisition of Vifor Pharma AG. CSL got all the necessary regulatory clearances required for Vifor's acquisition.

Pfizer Inc.:

Overview:

Pfizer Inc. is a multinational pharmaceutical company that also works in the biotechnology domain. It was established in 1849 and is headquartered in Manhattan, New York City. It is a manufacturer of various vaccines and medicines for cardiology, oncology, neurology, and immunology.

Product Portfolio:

RETACRIT: Retacrit is a kind of erythropoietin man-made protein made in a laboratory. It is an erythropoiesis-stimulating agent used to treat the anemia caused due to chronic kidney disease.

The global chronic kidney disease drugs market report would provide access to approximately 40+ market data tables, 45+ figures, and 200 (approximate) pages.

Table of Contents

1. Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The rising requirement for chronic kidney disease drugs
      • 4.1.1.2. Increasing technological advancements
    • 4.1.2. Restraints:
      • 4.1.2.1. High cost of chronic kidney disease drugs
      • 4.1.2.2. Risk associated with CKD drugs
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces
  • 5.2. Unmet Needs
  • 5.3. Epidemiology
  • 5.4. Supply chain Analysis
  • 5.5. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Drug Class

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 7.1.2. Market Attractiveness Index, By Drug Class
  • 7.2. Calcium Channel Blockers*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. ACE Inhibitors
  • 7.4. B- Blockers
  • 7.5. Diuretics
  • 7.6. Erythropoiesis-Stimulating Agents (ESAS)
  • 7.7. Others

8. By Route of Administration

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 8.1.2. Market Attractiveness Index, By Route of Administration
  • 8.2. Oral*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Subcutaneous
  • 8.4. Intravenous

9. By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Distribution Channel
    • 9.1.2. Market Attractiveness Index, By Distribution Channel
  • 9.2. Hospital Pharmacies*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Retail Pharmacies
  • 9.4. Online Pharmacies
  • 9.5. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), Distribution Channel
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), Distribution Channel
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. The U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), Distribution Channel
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), Distribution Channel
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), Distribution Channel
    • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking
  • 11.4. List of Key Companies to Watch

12. Company Profiles

  • 12.1. Pfizer Inc.
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Sanofi S.A.
  • 12.3. F. Hoffmann-La Roche Ltd.
  • 12.4. Teva Pharmaceutical Industries Ltd.
  • 12.5. AstraZeneca Plc.
  • 12.6. Kissei Pharmaceutical Co
  • 12.7. AbbVie Inc.
  • 12.8. GlaxoSmithKline Plc
  • 12.9. Amgen Inc.
  • 12.10. Akebia Therapeutics

LIST NOT EXHAUSTIVE

13. Global Chronic Kidney Disease Drugs Market- DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us